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Abstract 
Background: Ulcerative colitis (UC) is one major form of inflammatory bowel disease. The cause and the pathophysi-
ology of the disease are not fully understood and we therefor aim in this study to identify important pathophysiologi-
cal features in UC from proteomics data.
Methods: Colon mucosa biopsies from inflamed tissue of untreated UC patients at diagnosis and from healthy 
controls were obtained during colonoscopy. Quantitative protein data was acquired by bottom-up proteomics and 
furthermore processed with MaxQuant. The quantitative proteome data was analyzed with Perseus and enrichment 
data was analyzed by ClueGO for Cytoscape.
Results: The generated proteome dataset is to-date the deepest from colon mucosa biopsies with 8562 identified 
proteins whereof 6818 were quantified in > 70% of the samples. We report abundance differences between UC and 
healthy controls and the respective p values for all quantified proteins in the supporting information. From this data 
set enrichment analysis revealed decreased protein abundances in UC for metallothioneins, PPAR-inducible proteins, 
fibrillar collagens and proteins involved in bile acid transport as well as metabolic functions of nutrients, energy, 
steroids, xenobiotics and carbonate. On the other hand increased abundances were enriched in immune response 
and protein processing in the endoplasmic reticulum, e.g. unfolded protein response and signal peptidase complex 
proteins.
Conclusions: This explorative study describes the most affected functions in UC tissue. Our results complemented 
previous findings substantially. Decreased abundances of signal peptidase complex proteins in UC are a new 
discovery.
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Background
Ulcerative colitis (UC) is a form of inflammatory bowel 
disease (IBD). The chronic inflammation of the colon in 
UC starts at the rectum and can progress continuously 
to proximal colon parts. UC affects 0.51% of the Euro-
pean and 0.25% of the North American population, with 
increasing prevalence [1]. The disease has a complex 
pathophysiology and the exact disease causes remain 
unclear. A genetic component, environmental factors, 
defects of the epithelial barrier, and dysregulated immune 
responses are involved [2].
Pathophysiological changes likely lie or are reflected in 
the abundance and state of proteins, the major functional 
units in every tissue. The proteomic analysis of colon 
biopsies affected by UC gives data on these changes at 
the main site of the disease. Advances in sample prepa-
ration, instrumentation, and analysis software allow for 
increasing proteome coverage and improved quantifica-
tion. Higher proteome coverage, growing and new path-
way databases, and improved software packages benefit 
comprehensive enrichment analyses of tissues.
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Proteomic studies with different designs regarding sam-
ples and analytical method were previously conducted 
on colon mucosa affected by UC. Inflamed mucosa from 
untreated patients at UC debut [3] as well as macro-
scopically normal mucosa from treated UC patients [4] 
have been compared to biopsies from healthy controls 
in previous studies. A comparison of inflamed mucosa 
from untreated UC patients with mucosa from healthy 
controls as well as from Crohn’s disease patients was 
conducted on pediatric patients [5]. Another study com-
pared inflamed and non-inflamed tissue from the same 
patients [6]. Despite the differences in the study designs, 
the studies present remarkably similar proteome changes 
[3]. They revealed novel insights into the UC pathophysi-
ology, e.g. the role of neutrophil extracellular traps [4] 
and S100 proteins [3]. They also identified biomarkers for 
differentiating between UC and Crohn’s disease [5] and 
between pancolitis and partial colitis [7]. Furthermore, 
multiple studies investigated specific proteins of interest 
and their functions in UC, such as inducible nitric oxide 
synthase (NOS2) [8] and histaminase (AOC1) [9].
However, despite the challenges in extracting biologi-
cal information from omics data and the shortcomings of 
focusing on proteins with the highest fold-changes [10], 
enrichment analyses were not the main scope of previ-
ous proteomics studies on UC. Omics studies typically 
produce large amounts of data. Especially in experiments 
with strong phenotypes these datasets can contain so 
many significant findings that a sensible interpretation 
without additional statistical analyses is barely possible. 
Interpretations based on only the highest fold-changes 
in such a dataset disregard large amounts of data and fail 
to recognize functional changes as a result of multiple 
moderately different abundances. Moreover, the biologi-
cal interpretation is prone to be arbitrary, and it has fur-
ther disadvantages. Enrichment analyses can overcome 
these difficulties [10] and the enrichment factors give an 
additional indication for the importance of the respective 
functions for the disease pathophysiology.
Beside proteomics, transcriptomic approaches have 
been applied to investigate UC [11]. These studies show 
differential mRNA expressions in UC tissue. The patho-
physiological implications of these finding however are 
less clear because the correlation of mRNA and protein 
abundances is poor. The cause for that low correlation is 
that both the translation and the degradation of proteins 
are subject to several regulation mechanisms that are 
independent of mRNA levels [12].
We conducted a comprehensive enrichment analysis 
on a proteomics dataset of 8562 identified proteins from 
colon mucosa biopsies.
Materials and methods
Patients included and biopsies collection
Mucosal biopsies were collected from newly diagnosed 
treatment-naïve UC patients in Norway. The UC diag-
nosis was established upon clinical, endoscopic and his-
tological criteria defined by the European Crohn and 
Colitis Organization (ECCO) guidelines [13]. Further-
more, the degree of inflammation was evaluated during 
colonoscopy using the scoring system of ulcerative coli-
tis disease activity index (UCDAI) [14]. Moreover, TNF 
mRNA levels were measured by real-time PCR to assess 
the level of UC activity [15]. Subjects admitted for a can-
cer screening and with normal colonoscopy and histo-
logical findings served as healthy controls. None of the 
recruited subjects suffered from irritable bowel disease 
and they were not on nonsteroidal anti-inflammatory 
drug medication prior to the colonoscopy. The biop-
sies from the UC patients were obtained from the most 
inflamed area in rectum or sigmoid colon. Biopsies from 
the control group were obtained from the rectum. From 
each study participant, 3 adjacent biopsies were obtained 
from the inflamed mucosa. One biopsy was immediately 
immersed in RNAlater (Qiagen, Germany). The second 
biopsy was frozen immediately in a dry cryotube tube 
at − 70  °C until further analysis. The third biopsy was 
obtained for ordinary histological examinations (hae-
matoxylin and eosin staining). 17 patients with debut of 
UC and 15 healthy controls were recruited as shown in 
Table 1.
Table 1 Baseline characteristics in patients included at debut of ulcerative colitis and in healthy controls (see “Patients 
included and biopsies collection” and “Baseline characteristics” sections for further details)
UCDAI score and Geboes index averages calculated from available data for 15 and 16 patients, respectively
Study group Number 
of subjects
Average age (SD) Sex 
female/
male








UC patients 17 39.4 (16.7) 4/13 14,350 (16,725) 8.7 (2.2) 7.9 (3.8) 2 Proctitis
9 left sided UC
6 Extensive UC
Healthy control 15 51.9 (14.3) 5/10 4500 (2400) – – –
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Baseline characteristics
The baseline characteristics are shown in Table  1 (see 
Additional file 1: Table 1). All subjects included showed 
typical histological findings according to UC and normal, 
non-inflamed mucosa, respectively.
Sample preparation
Samples were homogenized with 250  µl cooled lysis 
buffer [8  M urea, 5% sodium deoxycholate (SDC), 
100  mM triethylammonium bicarbonate buffer pH 8.5 
(TEAB)] in MagNA Lyser Green Bead tubes (Roche Diag-
nostics AG, Rotkreuz, Switzerland) with a MagNA Lyser 
Instrument (Roche Diagnostics AG, Rotkreuz, Switzer-
land) for 35 s at 6500 rpm. Lysates were frozen at − 70 °C 
until further sample preparation. All samples and stand-
ards were diluted/produced to contain 5 mM TEAB for 
the BCA assay (Pierce™ BCA Protein Assay Kit, Thermo 
Fisher Scientific). The assay was performed according to 
the manufacturer’s protocol. Lysate aliquots of 60 µg pro-
tein were transferred to Protein LoBind tubes (Eppen-
dorf AG, Hamburg, Germany). Disulfide bridges were 
reduced with 1,4-dithiothreitol (DTT) at a concentration 
of 5 mM by incubation at 54 °C for 30 min. Cysteins were 
alkylated with 15 mM iodoacetamide (IAA) and incuba-
tion for 30  min at room temperature in the dark. DTT 
solution corresponding to a final concentration of 5 mM 
was added to remove excess IAA. Lys-C predigestion was 
performed under gentle agitation for 8  h at 37  °C with 
0.6 µg Lys-C (enzyme-to-protein ratio 1:100, w/w, Wako 
Chemicals GmbH, Neuss, Germany) in a buffer con-
taining 1 mM calcium chloride, 6 M urea, and 100 mM 
TEAB. Calcium chloride solution, 3 µg trypsin (enzyme-
to-protein ratio 1:20, w/w, Sequencing Grade Modified 
Trypsin, Promega Corporation, Madison, USA), water, 
and 1  M TEAB were added to a final concentration of 
1 mM calcium chloride, 1 M urea, and 100 mM TEAB. 
Tryptic digestion was performed under gentle agitation 
for 16 h at 37 °C.
Equal peptide amounts from each sample were com-
bined to produce a standard mixture, which was subse-
quently labelled with TMT126. Aliquots corresponding 
to 25  µg peptides were labelled with the remaining 
TMTsixplex isotopes according to the manufacturer’s 
protocol. 0.4 mg TMT reagent were used for 25 µg pep-
tides from samples with starting protein concentrations 
≥ 2200  µg/ml. Higher amounts of TMT reagent were 
used for lower starting concentrations (see Additional 
file 1: Table 2).
The differently labelled peptides were mixed in equal 
amounts to in total 100  µg peptides. The digests were 
acidified with 50% formic acid (FA) to a final concentra-
tion of 2.5% FA and pH ≤ 2. The samples were centrifuged 
at 16,000  g for 15  min and the supernatants were care-
fully transferred to fresh tubes. Acetonitrile was removed 
by evaporation in a vacuum concentrator.
Trifluoroacetic acid (TFA) was added to a concentra-
tion of 0.1%. The samples were fractionated with Pierce™ 
High pH Reversed-Phase Peptide Fractionation Kit 
(Thermo Fisher, Rockford, USA) according to the manu-
facturer’s protocol. Samples exceeding 300 µl were step-
wise loaded with 2 min centrifugation after each loading. 
The fractions were dried in a vacuum concentrator and 
redissolved in 10  µl 0.1% TFA for subsequent LC–MS/
MS analyses.
LC–MS/MS
The nano-LC–MS/MS analysis was performed on a 
Q Exactive mass spectrometer coupled to an EASY-
nLC 1000 system (Thermo Fisher Scientific, Bremen, 
Germany).
Shortly, 2.0 µg peptides, as measured with a Nanodrop 
2000 (Thermo Fisher Scientific, Bremen, Germany) at a 
wavelength of 205 nm and extinction coefficient 31 mg/
ml [16], per sample were injected. They were concen-
trated on a reversed-phase trap column and subsequently 
separated on a reversed-phase main column. A binary 
solvent gradient of 0.1% FA (solvent A) and 0.1% FA in 
acetonitrile (solvent B) was used. The ACN proportion 
was increased from 0 to 5% over 19 min, further to 30% 
at 180 min and to 100% at 200 min. A detailed descrip-
tion of the LC–MS/MS conditions can be found in the 
supporting information (see Additional file 1).
Data evaluation
The raw data was analyzed with MaxQuant against a Uni-
Prot fasta file of all human proteins (see Additional file 1) 
[17, 18]. Further analyses were performed with Perseus 
[19] and Cytoscape/ClueGO [20, 21].
The data processing and visualization in Perseus is 
partially based on a recently published protocol by the 
Perseus developers [22]. The intensities were log2-trans-
formed in Perseus, and the entries were filtered for the 
labels “potential contaminant”, “reverse” and “only iden-
tified by site”. Standard intensities were subtracted from 
the corresponding sample intensities and the resulting 
intensities Z-score transformed (matrix access: columns), 
which returns the normalized values (see Additional 
file 1).
Statistics and generation of figures and lists
Statistical analyses were performed in Perseus. The 
samples were assigned to the groups UC patients and 
healthy controls, respectively, and the groups contain-
ing the separate values for each sample were compared 
to each other with a two-sample test. Proteins were 
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annotated with gene ontology terms from the databases 
GOBP (biological process), GOMF (molecular func-
tion), GOCC (cellular component) [23], KEGG [24], 
GSEA [25], UniProt keywords [18], InterPro [26], Reac-
tome [27], and PROSITE [28]. The lists and the article 
figures were prepared in Perseus and the Cytoscape app 
ClueGO (see Additional file 1). The WikiPathways data-
base was used for the ClueGO analysis [29]. Pathways 




The proteomes of UC and healthy tissue differed strongly, 
as shown in Fig. 1. We present the 20 proteins with the 
highest abundance increases and decreases, respectively, 
in Table 2. The Pearson correlations of normalized inten-
sities (see Additional file 1) were higher when samples of 
the same group were compared (i.e. UC to UC, or healthy 
control to healthy control) than when UC samples were 
compared to healthy controls (Fig.  1a). Also the hierar-
chical clustering of the sample correlations resulted in 
Fig. 1 Exploratory analysis. a Hierarchical clustering of the correlation coefficients of 6829 protein intensities (proteins quantified in at least 70% of 
the samples) after normalization shows a clear separation between ulcerative colitis (UC) and healthy controls. The two replicates (labeled with repl) 
show the highest correlations. b Multi-scatter plot of the averaged profiles for UC2, 3, 4, 6, 7, 11, 13, 14, and 16 (UC a), UC1, 5, 8, 9, 10, 12, 15, and 17 
(UC b), H3, 4, 5, 6, 7, 8, 10, and 11 (H a), and H1, 2, 9, 12, 13, 14, and 15 (H b). The sample assignments to the groups a and b, respectively, are random. 
Blue numbers indicate Pearson correlation values. The averaged profiles show high correlations within the groups, and low correlations between 
the groups. c Principal component analysis (PCA) separates UC strongly from healthy controls in component 1 (39.9%)
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separate grouping of UC and healthy samples (Fig.  1a). 
In addition averaged profiles showed high Pearson cor-
relations (> 0.7) for comparisons within the groups UC 
and healthy, respectively, and low correlations (< 0.1) for 
comparisons of UC to healthy (Fig.  1b). Several multi 
scatter plots were investigated with random samples 
Table 2 20 proteins with highest abundance increase and decrease, respectively, in UC patients as compared to healthy 
controls
Included are only significantly different proteins as determined in the two-sample test comparing the groups UC patients and healthy controls (see Additional file 1). 
Only the first majority protein ID for each identification is given, for further IDs see Additional file 2
Ratio UC/H Protein name Gene names Majority protein ID − Log p value
Proteins of increased abundance in UC compared to healthy controls
10.12 Kinesin-like protein KIF26B B7WPD9 10.55
6.72 Protein S100-A8 S100A8 P05109 8.41
6.70 Cathelicidin antimicrobial peptide CAMP J3KNB4 9.71
6.17 Protein S100-A9 S100A9 P06702 8.07
4.95 Protein S100-A12 S100A12 P80511 8.36
4.73 Neutrophil defensin 1 DEFA1 P59665 7.02
4.47 Lactotransferrin LTF;HEL110 E7EQB2 9.42
4.39 Myeloblastin PRTN3 P24158 7.49
4.18 Neutrophil gelatinase-associated lipocalin NGAL;LCN2 B2ZDQ1 13.57
3.54 Neutrophil elastase ELANE;ELA2 P08246 7.48
3.51 Azurocidin AZU1 P20160 8.36
3.49 Cysteine-rich secretory protein 3 CRISP3 J3KPA1 6.44
3.22 Myeloperoxidase MPO P05164-2 9.05
3.20 Bactericidal permeability-increasing protein BPI A2NX48 4.31
3.18 60S ribosomal protein L14 RPL14 P50914 1.62
3.17 Bactericidal permeability-increasing protein BPI P17213 8.26
3.16 Lysozyme LYZ B2R4C5 8.50
3.12 Marginal zone B- and B1-cell-specific protein MZB1 Q8WU39 14.01
3.07 Ig heavy chain V-I region EU IGHV1-69-2 P01742 3.98
3.01 Ficolin-1 FCN1 O00602 6.65
Proteins of decreased abundance in UC compared to healthy controls
0.12 Hydroxymethylglutaryl-CoA synthase, mitochondrial HMGCS2 A0A140VJL2 14.77
0.17 Fatty acid-binding protein, liver FABP1 Q6FGL7 14.41
0.19 3-keto-steroid reductase HSD17B7;hCG_2024989 P56937-2 14.32
0.24 Sulfate transporter SLC26A2 P50443 18.52
0.26 Tumor necrosis factor alpha-induced protein 8-like protein 3 TNFAIP8L3 Q5GJ75 5.42
0.29 Carbonic anhydrase 2 HEL-76;CA2 V9HW21 12.09
0.30 Selenium-binding protein 1 HEL-S-134P;SELENBP1 V9HWG1 15.36
0.33 cAMP-dependent protein kinase inhibitor beta PKIB Q5T0Z6 7.57
0.34 Chloride anion exchanger SLC26A3;DKFZp686P10213 P40879 10.33
0.35 UDP-glucuronosyltransferase 2A3 UGT2A3 Q6UWM9 14.95
0.36 Chymotrypsin-C CTRC Q99895 5.37
0.36 Hyaluronan and proteoglycan link protein 3 HAPLN3 A0A024RC58 8.55
0.37 Calcium-activated chloride channel regulator 1 CLCA1 A8K7I4 6.68
0.37 Tissue alpha-l-fucosidase FUCA1 P04066 10.42
0.37 Phospholipase A(2) PLA2G1B F8W062 2.71
0.38 UDP-glucuronosyltransferase 2B17 UGT2B17;UGT2B15 O75795 3.10
0.38 Aquaporin-8 AQP8 Q53GF6 7.86
0.38 Mimecan OGN Q7Z532 9.66
0.39 Cadherin-17 CDH17 Q12864 17.16
0.39 Alcohol dehydrogenase 1C ADH1C P00326 10.05
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from UC patients or healthy controls in each group, and 
all showed the same trend with high correlations inter-
nally in the UC and healthy sample groups. Upon unsu-
pervised investigation by principal component analysis 
(PCA) (Fig. 1c) a strong separation of UC and healthy in 
component 1 which explains 39.9% of the variance was 
observed. To investigate possible biases we controlled for 
grouping by gender, and such grouping did not occur.
Comparison with previous proteomics studies on UC
The in total 8562 identified proteins provided the so far 
deepest view into the proteome of human colon mucosa 
and of UC. We report the abundance changes includ-
ing p values for all quantified proteins (see Additional 
file 2: Excel file). 6818 of these proteins were quantified 
in at least 70% of the samples and were subject to enrich-
ment analysis. Our data confirmed and extends previ-
ous findings, but also includes novel findings, such as 
the increased abundance of signal peptidase complex 
proteins. We searched PubMed for the terms “ulcerative 
colitis proteomics” and reviewed the titles and abstracts 
to select the relevant studies. Additionally we included 
studies previously known to the authors, totaling to 7 
studies for the comparison [3–9]. The present study was 
largely in agreement with those previous studies about 
the direction of abundance changes of differently abun-
dant proteins. However, the magnitudes of the changes 
differed.
Functional analysis
Hierarchical clustering of the 596 most differently abun-
dant proteins (8.7% of all proteins quantified in > 70% of 
samples; s0 = 2, FDR = 0.01) revealed three major clus-
ters (Fig. 2). The proteins which were higher abundant in 
UC divided into two clusters, a small cluster of 20 pro-
teins with a more pronounced abundance change in a 
subgroup of samples, and a large cluster of 247 proteins. 
The lower abundant proteins formed one cluster of 313 
Fig. 2 Clustering of the 596 most differently abundant proteins between ulcerative colitis (UC) and healthy controls. a Hierarchical clustering 
reveals three main protein clusters. Low abundances are indicated in blue, high abundances in red. b Protein abundance profiles of the three main 
clusters. 1: minor cluster of 20 proteins (including calprotectin) with increased abundance in UC, with a subgroup of UC samples showing a more 
pronounced increase. 2: major cluster of 247 proteins with increased abundance in UC. 3: Cluster of 313 proteins with a decreased abundance in UC
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proteins. In total 16 proteins were outside these three 
clusters.
The extraction of biological information from omics 
datasets is a major challenge. Enrichment analyses can 
overcome some of the difficulties [10]. Enrichment analy-
ses annotate categorical terms (e.g. functions, localiza-
tions, pathways) to proteins and subsequently determine 
which terms are overrepresented among the differently 
abundant proteins compared to the entire dataset of 
quantified proteins. Knowledge about the involved path-
ways and functions can help to understand the disease, 
understand complications, and develop new treatment 
options.
Abundance changes found in tissue proteomics could 
result from differential regulation of the protein abun-
dances in cells, but also from changes of the cell popu-
lation (e.g. from the migration of immune cells into 
inflamed tissue in UC [11]) or the extracellular matrix. 
It seems plausible that each of these factors affects all 
measured abundances in such an experiment to varying 
degrees.
Lists of the enriched gene ontology terms among pro-
teins which were found to be differently abundant in UC 
as compared to healthy tissue, and a list of the proteins 
which contributed to the functions discussed in the fol-
lowing are provided as Additional file 2: Excel file.
This article can neither cover all enriched terms we 
found, nor can it discuss the impact of each differently 
abundant protein on a function or the magnitude of 
its abundance change in detail. We therefore strongly 
encourage the reader to consult the above mentioned 
tables for further information on functions and proteins 
of interest.
Lower abundant in UC
321 proteins showed decreased abundances in UC 
as compared to healthy control samples. 313 of these 
grouped into one cluster (Fig.  2, cluster 3). Functional 
analysis revealed that metabolic pathways were overrep-
resented among the proteins with decreased abundance 
in UC. The enrichment of proteins with decreased abun-
dances in our dataset affects short-chain and long-chain 
fatty acid, ketone body and amino acid (particularly 
tryptophan) metabolism as well as the tricarboxylic acid 
(TCA) cycle (see Additional file 1: SuppPathway1–4) and 
the electron transport chain (ETC; Fig. 3a).
The observed abundance decreases of butyrate uti-
lizing proteins are in line with previous studies which 
show a decreased butyrate metabolism by UC tissue. 
Butyrate is a short-chain fatty acid (SCFA) and the main 
energy source of healthy colon mucosa [31]. It was pre-
viously hypothesized that ulcerative colitis is an energy-
deficiency disease resulting from the failure to utilize 
butyrate [31]. Colonocytes convert a part of the butyrate 
to ketone bodies [32]. Our data showed that proteins 
related to this specific utilization of butyrate were lower 
abundant in UC. Several studies have investigated 
whether butyrate has a positive effect on inflamed colon 
tissue, however the results of these studies are conflicting 
[33].
The decreased protein abundances also affected the 
transport and metabolism of the long-chain fatty acids 
(LCFA), i.e. the long carbon chain analogs of SCFAs. 
LCFAs have an ambiguous role in ulcerative colitis. Lin-
oleic acid increases the chances of developing ulcerative 
colitis [34]. Omega-3 fatty acids, such as docosahexae-
noic acid (DHA), may reduce the chance of developing 
the disease [35]. Studies on the efficacy of omega-3 fatty 
acids in the treatment of ulcerative colitis show contro-
versial results. Systematic reviews however conclude that 
large high-quality studies fail to show positive effects, 
and that there is no sufficient evidence for the efficiacy of 
omega-3 fatty acids in the treatment of UC [36, 37].
Mitochondrial enzymes involved in the metabolism of 
SCFA and LCFA as well as the tricarboxylic acid (TCA) 
and the electron transport chain (ETC) were found in our 
dataset to be low abundant in UC. These findings reflect 
a mitochondrial dysfunction which possibly contributes 
to the proposed energy deficiency [38].
Proteins related to nuclear receptors were of decreased 
abundance in UC. Peroxisome proliferator-activated 
receptor (PPAR)-inducible proteins were lower abun-
dant in UC (Fig. 3). The changes in the LCFA transport 
and the PPAR pathway are interdependent. Activation 
of the intracellular PPAR receptors by LCFA demands 
the import of the fatty acids into the cell and the trans-
port within the cell. One protein involved in the trans-
port into the cell is CD36 which is low abundant in UC 
tissue. Fatty acid binding proteins (FABP) facilitate 
the transport within the cell [39]. Four FABPs (FABP1, 
FABP2, FABP4, and FABP5) are among the proteins with 
the lowest relative abundance in UC tissue compared to 
healthy tissue. A decreased transport of LCFA might in 
turn be partially causative for the decreased abundances 
of PPAR-inducible proteins, such as ACOX1, HMGCS2, 
FABP1, and PCK1 [40]. In accordance with a previous 
study [41], we found the vitamin D3 receptor NR1i1 to be 
lower abundant in UC tissue. However, we observed no 
general abundance changes of proteins regulated by this 
receptor. Previous studies found decreased abundances 
of hepatocyte nuclear factor 4 alpha (HNF4A) in UC and 
suggested a role in the disease pathophysiology [42]. Our 
data supports these findings.
All detected metallothioneins—MT1H, MT2A, and 
MT1F—were found to be lower abundant in UC tis-
sue compared to healthy controls. Metallothioneins are 
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small, cysteine-rich proteins, which bind heavy metal 
cations. Our findings confirmed several previous stud-
ies, which concluded that the decreased metallothio-
nein abundances may result in an inefficient antioxidant 
response in the mucosa and in turn contributes to the 
IBD pathophysiology [43]. However, other studies pre-
sent conflicting results and conclusions [44].
Histamine is the major mediator of mast cells and 
contributes to the immuno-inflammatory reaction 
in IBD. Previous studies showed increased histamine 
secretion and levels in UC affected tissues [45] and 
decreased histaminase (AOC1) activity [9]. The pre-
sent study revealed that both major histamine degrad-
ing enzymes—Histaminase (AOC1) and histamine 
N-methyltransferase (HNMT)—were lower abundant 
in UC tissue compared to healthy tissue (not based on 
enrichment analysis). This finding constitutes a plau-
sible causative explanation for some of the previously 
reported findings on histamine in UC.
Fig. 3 Functional networks of differently abundant proteins in colon mucosa biopsies affected by ulcerative colitis compared to healthy controls. 
a Functional network of the 321 proteins with the strongest abundance decrease in ulcerative colitis compared to healthy tissue. Metabolic 
functions dominate this network, especially those located in the mitochondria. b Functional network of the 275 proteins with highest abundance 
increase in ulcerative colitis. Functions of the immune system characterize this network. Generated with ClueGO, Pathways: WikiPathways (updated: 
10.03.2018), pV ≤ 0.01
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Chemical compounds undergo phase I and phase II 
biotransformation reactions which make them more 
hydrophilic [46]. This allows their excretion with urine 
because the polar compounds are not reabsorbed in 
the kidneys [47]. Phase I reactions introduce or change 
functional groups by oxidation, reduction, or hydroly-
sis. In phase II reactions, enzymes attach hydrophilic 
endogenous compounds [46]. Our data showed that the 
abundances of a large proportion of both phase I and 
phase II enzymes are decreased in UC. A decrease of 
xenobiotic metabolism gene products in UC was shown 
earlier on mRNA level [48]. The affected phase II 
enzymes are involved in sulfonation, glucuronidation, 
and glutathione conjugation. Proteins related to both 
phase 1 (monoamine oxidase A, MAOA) and phase 2 
metabolism (sulfotransferases) of catecholamines were 
found in our dataset to be less abundant in UC. This 
could contribute to previously found increases of nor-
epinephrine in rectal UC mucosa [49].
Synthetic steroids are an important treatment option 
for ulcerative colitis. Our data showed impairments in 
the steroid metabolism in UC. This suggests a role of 
endogenous steroids in the pathophysiology of the dis-
ease. The hydroxysteroid dehydrogenases HSD11B2, 
HSD17B11, HSD17B2, and HSD17B7 were among the 
most down-regulated proteins in UC (HSD17B8 is 
downregulated to a lesser degree). The abundances of 
HSD17B4, HSD17B10, and HSD17B12 were not differ-
ent in UC from healthy tissue. Decreased abundances 
of HSD11B2 [50] and HSD17B7 [3] have been reported 
previously. Our data furthermore showed that pro-
teins related to the transport of bile acids are enriched 
among the lower abundant proteins, which supports 
findings of a previous study [41]. Pathway mapping 
shows abundance decreases of proteins involved in the 
neutral pathway of bile acids biosynthesis (Additional 
file  1: SuppPathway5). However, the implications of 
this finding are not clear, because bile acids are primar-
ily synthesized in hepatocytes, whereas there is no evi-
dence of bile acid synthesis in enterocytes [51].
The carbonic anhydrases CA1, CA2, CA4, and CA12 
were found to be lower abundant in UC. CA3 was the 
only quantified but not significantly lower abundant 
carbonic anhydrase. A decreased abundance in UC was 
reported earlier for CA1 [52].
Fibrillar collagens are a subgroup of collagens and 
provide three-dimensional frameworks for tissues 
and organs [53]. The fibrillar collagens were enriched 
among the proteins that were of decreased abundance 
in UC. Proteins that are involved in collagen degrada-
tion, e.g. metalloproteinases, on the other hand were 
enriched among the proteins with increased abundance 
in UC (see below). This finding is in accordance with 
a previous study on the role of collagen degradation in 
IBD [54].
Higher abundant proteins in UC
As expected, many proteins with increased abundance in 
UC are involved in inflammatory and immune processes 
(Fig.  3b). Proteins related to neutrophils (e.g. NADPH 
oxidase complex proteins which generate superoxide, 
metalloproteinases) and B cells (e.g. V and C regions 
of immunoglobulins) were highly enriched. This could 
result from a tissue infiltration by these immune cells.
The higher abundant proteins divided into two main 
clusters under hierarchical clustering (Fig.  2, clusters 1 
and 2). The UC patients with high cluster 1 protein abun-
dances (UC1, UC2, UC5, UC8, UC15, UC17) grouped 
together (Fig. 2a, b). Cluster 1 contained proteins occur-
ring in neutrophils, among these Protein S100A8 and 
Protein S100A9 which together form the calprotectin 
complex (see Additional file 1: Table 3). Several proteins 
(calprotectin, S100A12, lactotransferrin) of the minor 
cluster have been used to differentiate between IBD and 
non-IBD [55]. Interestingly, the average Geboes index in 
the patient cluster with high cluster 1 protein abundances 
is 11.0 (SD = 3.1), while it is 6.5 (SD = 3.2) for the other 
patients.
Our data showed that inducible nitric oxide synthase 
(NOS2) is higher abundant in UC tissue (not based on 
enrichment analysis). NOS2 produces nitric oxide (NO) 
which has various physiological roles as a messenger mol-
ecule. It functions most prominently as a vasodilator [56], 
but it is also involved in the immune system [57]. NO is 
directly toxic to pathogens, induces or suppresses apop-
tosis, and regulates the immune reaction [58]. Excess NO 
is cytotoxic and induces cell death. NOS2 is inducible 
by inflammation, infection and other stimuli. Increased 
NOS2 abundances in UC were shown earlier by immu-
nostaining [8] and our results confirm these findings.
Proteins with functions in protein processing in the 
endoplasmic reticulum (ER) are overrepresented among 
the proteins which were more abundant in UC. Also 
unfolded protein response (UPR) and signal peptidase 
complex (SPC) proteins are related to protein process-
ing, located in the ER, and enriched among proteins with 
increased abundances in UC. UPR has previously been 
identified as one factor in the pathophysiology of ulcera-
tive colitis [59]. The enrichment of SPC proteins among 
proteins with increased abundances in UC is a novel find-
ing from our data.
However, ER proteins were not generally higher 
abundant. For instance, many metabolic enzymes are 
located in the ER and enriched among the proteins with 
decreased abundances (e.g. UDP-glucuronosyltrans-
ferases, see “Lower abundant in UC” section).
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The SPC is not inherently inflammatory. Nonetheless 
its proteins were among those with the highest abun-
dance increases in UC. The SPC is located in the mem-
brane of the endoplasmic reticulum and cleaves the 
signal peptide cotranslationally from nascent proteins 
[60]. The SPC subunits SPCS1, SPCS2, and SPCS3 and 
the SPC catalytic subunit SEC11C were more abundant 
in UC. They furthermore showed highly similar abun-
dance profiles (Additional file 1: Figure 3). The SPC cata-
lytic subunit SEC11 however does not follow this pattern 
and was similarly abundant in UC and healthy tissue.
Accumulation of unfolded and misfolded proteins 
causes stress to the endoplasmic reticulum. The UPR 
aims to remove these proteins. To achieve this, the cell 
stops the translation of further proteins, degrades mis-
folded proteins, and produces chaperones, which correct 
the protein folding. Our data showed strong enrichment 
of proteins related to UPR, response to ER stress, and 
the ER chaperone complex among the higher abundant 
proteins in UC. Specifically, several chaperones that can 
be induced by ATF6 alpha (HSP90B1, calreticulin [61], 
and HSPA5 [62]), which plays a central role in UPR, were 
enriched. Our findings support previous assumptions 
that the UPR may play a role in the pathophysiology of 
UC.
Foreseeable applications
The functional changes we observed in the present 
study allow for hypothesis generation for treatment 
approaches.
Alterations of metabolic pathways in ulcerative coli-
tis imply that nutritional interventions directed at the 
respective metabolites could be effective in the treat-
ment of the disease. For instance, decreased metal-
lothionein abundances indicate that the detoxification of 
heavy metals and the utilization of polyvalent metal ions 
could be impaired. Considering the decreased detoxi-
fication capacities, reduced intake or chelation of toxic 
heavy metals might have beneficial effects. On the other 
hand, the supplementation of essential polyvalent metal 
ions could be advantageous. Furthermore, the decreased 
metabolic and transport capabilities related to butyrate 
contribute probably to the energy deprivation of colo-
nocytes. Previous studies investigated the treatment of 
UC with butyrate and other SCFA. But the pathophysi-
ological changes we observed related to the utilization 
of those compounds imply that supplementation with a 
later metabolite such as beta-hydroxybutyrate might be 
preferable. Beta-hydroxybutyrate is a ketone body that 
becomes systemically available after oral administration 
and has been used in the treatment of other pathophysi-
ological conditions [63, 64].
The enrichment of proteins related to signaling path-
ways such as PPAR designates the respective pathways 
as potential drug targets.
Abundance changes of single proteins may have 
similar implications, especially if they are known to 
be drugable. Proteins with high abundance differences 
between UC patients and healthy controls and high 
corresponding − Log p values are of potential interest 
as biomarker candidates. Proteins with these character-
istics are for instance SLC26A2, HMGCS2, and CD38 
(Additional file 1: Figure 4; Additional file 2).
However, further testing, clinical studies, and valida-
tion will be necessary before any clinical application.
Conclusions
Our study presents new evidence and complements 
previous findings about changes of biological functions 
in UC. The major novel findings of this study were the 
increased abundances of SPC proteins and the presence 
of two distinguished clusters of higher abundant pro-
teins, with the calprotectin complex proteins S100A8 
and S100A9 in the minor cluster 1. This cluster of 20 
proteins diverged from the abundance changes of the 
majority of proteins with increased abundances in UC 
that we observed in cluster 2.
In conclusion, abundances in UC tissue were 
increased compared to healthy controls for proteins 
related to the immune system and to protein processing 
in the ER, e.g. UPR and SPC proteins. Immune cell infil-
tration into the inflamed tissue contributes probably to 
the increased immune system protein abundances. The 
high abundance of UPR proteins indicates an ER stress 
response. Moreover, NOS2 which produces NO was 
higher abundant in UC tissue.
Lower abundant in UC were predominantly meta-
bolic proteins. These metabolic proteins comprise 
mitochondrial enzymes for the metabolization of 
SCFA and LCFA as well as proteins of the TCA cycle 
and the ETC. These changes are probably contribut-
ing to the previously reported mitochondrial dysfunc-
tion and energy deficiency of colonocytes in UC. The 
abundances of LCFA transport proteins were decreased 
which may be partially causative for the decreased 
abundances of PPAR-inducible proteins. Decreased 
abundances of histamine degrading enzymes probably 
contribute to the increased histamine levels in UC tis-
sue which were found in previous studies. Furthermore, 
abundances of proteins involved in phase I and phase 
II biotransformation were decreased, as well as the 
abundances of several metallothioneins, hydroxysteroid 
dehydrogenases, and carbonic anhydrases.
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We provide a list of all 8562 identified proteins includ-
ing the fold changes UC/H and p values as supporting 
information (see Additional file 2: Excel file).
Additional files
Additional file 1. Detailed method descriptions, additional figures and 
tables, mapping of metabolic pathways.
Additional file 2. Complete list of identified proteins including UC/
Healthy ratios and p-values, lists of gene ontology term enrichments, 
enriched functions discussed in the article and their proteins.
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